Patent US4495282A successfully refreshed from Google Patents.
US4495282A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for producing target cell lysis factor and uses therewith
Assignee: Hayashibara Seibutsu Kagaku Kenkyujo KK
•
Filing: 1982-07-21
•
Granted: 1985-01-22
•
Expires: 2002-07-21
Abstract
Abstract Target Cell Lysis Factor (TCLF) is produced by exposing a human cell line capable of producing TCLF to a TCLF inducer to induce TCLF production, and collecting and purifying the accumulated TCLF. The TCLF which is produced includes lymphotoxin and human Tumor Necrosis Factor (hTNF). The hTNF may be separated and purified. The human cell lines are preferably human leucocyte and human lymphoblastoid lines, such as BALL-1, TALL-1, NALL-1 Namalwa, MOLT-3, Mono-1, M-7002, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41 and CCRF-SB, as well as human cell lines which are obtainable by transforming normal human monocytes, or granulocytes. All of these human cell lines are multipliable by implanting them in a non-human warm-blooded animal, or alternatively, allowing them to multiply in a conventional-type diffusion chamber by which the nutrient body fluid of a non-human warm-blooded animal is supplied to them.
Inventors
- 👤 Haruo Ohnishi
- 👤 Masakazu Mitsuhashi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:50
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/525; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/808
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
98 words
A process for producing human Target Cell Lysis Factor (TCLF), comprising: implanting a human cell line selected from the group of cell lines consisting of BALL-1, TALL-1, NALL-1, Namalwa, MOLT-3, Mono-1, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41, and CCFR-SB in a non-human warm-blooded animal; feeding the animal to allow said human cell line to utilize the nutrient body fluid of the animal for its multiplication; exposing the multiplied human cells to a TCLF inducer under conditions appropriate to induce the accumulation of a substantial amount of TCLF by said cells; and recovering the accumulated TCLF.
Claim 2
Dependent Claim
98 words
A process for producing human Target Cell Lysis Factor (TCLF), comprising: implanting a human cell line selected from the group of cell lines consisting of BALL-1, TALL-1, NALL-1, Namalwa, MOLT-3, Mono-1, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41, and CCFR-SB in a non-human warm-blooded animal; feeding the animal to allow said human cell line to utilize the nutrient body fluid of the animal for its multiplication; exposing the multiplied human cells to a TCLF inducer under conditions appropriate to induce the accumulation of a substantial amount of TCLF by said cells; and recovering the accumulated TCLF.
Claim 3
Dependent Claim
71 words
A process in accordance with claim 1, wherein said exposing and recovering steps comprise: extracting and disaggregating the human cell line tumor formed in the animal to obtain the multiplied human cells; exposing the multiplied human cells to an effective amount of TCLF inducer on an in vitro culture medium under conditions appropriate to induce the accumulation of a substantial amount of TCLF; and recovering the accumulated TCLF from said culture.
Claim 4
Dependent Claim
28 words
A process in accordance with claim 1, wherein said TCLF inducer is a member selected from the group consisting of virus, nucleic acid, nucleotide, lectin, mitogen and endotoxin.
Claim 5
Dependent Claim
16 words
A process in accordance with claim 1, wherein said TCLF inducer is phytohaemagglutinin or concanavalin A.
Claim 6
Dependent Claim
35 words
A process in accordance with claim 1, wherein said TCLF is a glycoprotein with a molecular weight in the range of 1×10 4 -1×10 5 daltons and a saccharide content in the range of 5-45%.
Claim 7
Dependent Claim
41 words
A process in accordance with claim 1, wherein the TCLF contains at least one member of specimens having a molecular weight of about 1×10 4 -2×10 4 daltons, about 3.5×10 4 -5×10 4 daltons or about 7×10 4 -9×10 4 daltons.
Claim 8
Dependent Claim
30 words
A process as set forth in claim 1, wherein said TCLF contains a member selected from the group consisting of lymphotoxin, human Tumor Necrosis Factor (hTNF) and a mixture thereof.
Claim 9
Dependent Claim
143 words
A process for producing human Target Cell Lysis Factor (TCLF), comprising: suspending a human cell line selected from the group of cell lines consisting of BALL-1, TALL-1, NALL-1, Namalwa, MOLT-3, Mono-1, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41 and CCRF-SB in a diffusion chamber in which the nutrient body fluid of a non-human warm-blooded animal may be supplied to said human cell line; embedding or placing said chamber in or on a non-human warm-blooded animal in a manner such that the nutrient body fluid of said animal is supplied to the cell line within said chamber; feeding the animal to allow said human cell line to utilize said nutrient body fluid for its multiplication; exposing the multiplied human cells to a TCLF inducer under conditions appropriate to induce the accumulation of a substantial amount of TCLF; and recoving the accumulated TCLF.
Claim 10
Dependent Claim
143 words
A process for producing human Target Cell Lysis Factor (TCLF), comprising: suspending a human cell line selected from the group of cell lines consisting of BALL-1, TALL-1, NALL-1, Namalwa, MOLT-3, Mono-1, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41 and CCRF-SB in a diffusion chamber in which the nutrient body fluid of a non-human warm-blooded animal may be supplied to said human cell line; embedding or placing said chamber in or on a non-human warm-blooded animal in a manner such that the nutrient body fluid of said animal is supplied to the cell line within said chamber; feeding the animal to allow said human cell line to utilize said nutrient body fluid for its multiplication; exposing the multiplied human cells to a TCLF inducer under conditions appropriate to induce the accumulation of a substantial amount of TCLF; and recoving the accumulated TCLF.
Claim 11
Dependent Claim
63 words
A process in accordance with claim 8, wherein said exposing and recovering steps comprise: harvesting the multiplied human cells from said diffusion chamber; exposing the harvested multiplied human cells to an effective amount of TCLF inducer on an in vitro culture medium under conditions appropriate to induce the accumulation of a substantial amount of TCLF; and recovering the accumulated TCLF from said culture.
Claim 12
Dependent Claim
28 words
A process in accordance with claim 8, wherein said TCLF inducer is a member selected from the group consisting of virus, nucleic acid, nucleotide, lectin, mitogen and endotoxin.
Claim 13
Dependent Claim
16 words
A process in accordance with claim 8, wherein said TCLF inducer is phytohaemagglutinin or concanavalin A.
Claim 14
Dependent Claim
35 words
A process in accrdance with claim 8, wherein said TCLF is a glycoprotein with a molecular weight in the range of 1×10 4 -1×10 5 daltons and a saccharide content in the range of 5-45%.
Claim 15
Dependent Claim
41 words
A process in accordance with claim 8, wherein the TCLF contains at least one member of specimens having a molecular weight of about 1×10 4 -2×10 4 daltons, about 3.5×10 4 -5×10 4 daltons or about 7×10 4 -9×10 4 daltons.
Claim 16
Dependent Claim
30 words
A process as set forth in claim 8, wherein said TCLF contains a member selected from the group consisting of lymphotoxin, human Tumor Necrosis Factor (hTNF) and a mixture thereof.
Claim 17
Dependent Claim
46 words
A process for producing human Tumor Necrosis Factor (nTNF), comprising: culturing a human cell line capable of producing hTNF in the presence of an effective amount of a TNF inducer under conditions appropriate to induce the accumulation of a substantial amount of hTNF; and recovering hTNF.
Claim 18
Dependent Claim
46 words
A process for producing human Tumor Necrosis Factor (nTNF), comprising: culturing a human cell line capable of producing hTNF in the presence of an effective amount of a TNF inducer under conditions appropriate to induce the accumulation of a substantial amount of hTNF; and recovering hTNF.
Claim 19
Dependent Claim
70 words
A process in accordance with claim 15, wherein said culturing step comprises: implanting a human cell line capable of producing hTNF in a non-human warm-blooded animal; feeding the animal to allow said human cell line to utilize the nutrient body fluid of the animal for its multiplication; and exposing the multiplied human cells to a TNF inducer under conditions appropriate to induce the accumulation of a substantial amount of hTNF.
Claim 20
Dependent Claim
116 words
A process in accordance with claim 15, wherein said culturing step comprises; suspending a human cell line capable of producing hTNF in a diffusion chamber in which the nutrient body fluid of a non-human warm-blooded animal may be supplied to said human cell line; embedding or placing said chamber in or on a non-human warm-blooded animal in a manner such that nutrient body fluid of said animal is supplied to the cell line within said chamber; feeding the animal to allow said human cell line to utilize said nutrient body fluid for its multiplication; and exposing the multiplied human cells to TNF inducer under conditions appropriate to induce the accumulation of a substantial amount of hTNF.
Claim 21
Dependent Claim
72 words
A process as set forth in claim 16, wherein said exposing and recovering steps comprise: extracting and disaggregating the human cell line tumor, formed in the animal, to obtain the multiplied human cells; exposing the multiplied human cells to an effective amount of TNF inducer on an in vitro culture medium under conditions appropriate to induce the accumulation of a substantial amount of hTNF; and recovering the accumulated hTNF from said culture.
Claim 22
Dependent Claim
62 words
A process in accordance with claim 15, wherein said exposing and recovering steps comprise: harvesting the multiplied human cells from said diffusion chamber; exposing the harvested multiplied human cells to an effective amount of TNF inducer on an in vitro culture under conditions appropriate to induce the accumulation of a substantial amount of hTNF; and recovering the accumulated hTNF from said culture.
Claim 23
Dependent Claim
17 words
A process in accordance with claim 15, wherein said human cell line is a human lymphoblastoid line.
Claim 24
Dependent Claim
40 words
A process in accordance with claim 15, wherein said human cell line is a member selected from the group of cell lines consisting of BALL-1, NALL-1, TALL-1, Namalwa, MOLT-3, Mono-1, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM and CCFR-CB.
Claim 25
Dependent Claim
28 words
A process in accordance with claim 15, wherein said TNF inducer is a member selected from the group consisting of virus, nucleic acid, nucleotide, lectin, mitogen and endotoxin.
Claim 26
Dependent Claim
16 words
A process in accordance with claim 15, wherein said TNF inducer is phytohaemagglutinin or concavalin A.
References Cited (Backward Citations)
US4276282A
Cited
US4296025A
Cited
US4328207A
Cited
US4383036A
Cited
US4377513A
Cited
US4383034A
Cited
US4383035A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-01-22 | 1988-07-23 | 1989-01-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-01-22 | 1992-07-23 | 1993-01-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-01-22 | 1996-07-23 | 1997-01-22 | $7700.00 | Window Closed / Lapsed |